Status:
COMPLETED
Pharmaco Kinetic Variability of Infliximab in Rheumatoid Arthritis
Lead Sponsor:
University Hospital, Tours
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Brief Summary
Infliximab is a chimeric monoclonal antibody directed towards Tumor Necrosis Factor -alpha that is largely used in inflammatory diseases such as rheumatoid arthritis (RA). A relationship between dose...
Eligibility Criteria
Inclusion
- Rheumatoid arthritis according to ACR criteria
- Patient already receiving infliximab for more than 14 weeks
- No modification of the dose regimen of infliximab since the last infusion
- No modification of disease modifying anti rheumatic drugs since the last 4 weeks
Exclusion
- Surgery scheduled during the duration of the study
- Pregnancy
- infection, malignancy, immune reaction to infliximab or demyelinating diseases
Key Trial Info
Start Date :
November 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2009
Estimated Enrollment :
84 Patients enrolled
Trial Details
Trial ID
NCT00840957
Start Date
November 1 2007
End Date
November 1 2009
Last Update
April 9 2015
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
CHRU de Brest
Brest, France
2
CHRU de Nantes
Nantes, France
3
CHR d'Orléans
Orléans, France
4
CHRU de Poitiers
Poitiers, France